Your browser doesn't support javascript.
loading
Structural Basis for PPARα Activation by 1H-pyrazolo-[3,4-b]pyridine Derivatives.
Yoshida, Takuya; Oki, Hiroya; Doi, Michihiro; Fukuda, Syohei; Yuzuriha, Tomohiro; Tabata, Ryotaro; Ishimoto, Kenji; Kawahara, Kazuki; Ohkubo, Tadayasu; Miyachi, Hiroyuki; Doi, Takefumi; Tachibana, Keisuke.
Affiliation
  • Yoshida T; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan. yo@phs.osaka-u.ac.jp.
  • Oki H; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Doi M; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Fukuda S; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Yuzuriha T; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Tabata R; Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka, 573-0101, Japan.
  • Ishimoto K; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Kawahara K; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Ohkubo T; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Miyachi H; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Doi T; Drug Discover Initiative, University of Tokyo, 7-3-1 Hongo, Bynkyo, Tokyo, 113-0033, Japan.
  • Tachibana K; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Sci Rep ; 10(1): 7623, 2020 05 06.
Article in En | MEDLINE | ID: mdl-32376995
ABSTRACT
Small-molecule agonism of peroxisome proliferator-activated receptor α (PPARα), a ligand-activated transcriptional factor involved in regulating fatty acid metabolism, is an important approach for treating dyslipidemia. Here, we determined the structures of the ligand-binding domain (LBD) of PPARα in complex with 1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid derivatives, which were recently identified as PPARα-selective activators with markedly different structures from those of the well-known PPARα agonists fibrates. The crystal structures of the complexes showed that they form a canonical hydrogen-bond network involving helix 12 in the LBD, which is thought to be essential for PPARα activation, as also observed for fibrates. However, the phenyl side chain of the compounds occupies a small cavity between Ile272 and Ile354, which is rarely accessed by fibrates. This unique feature may be essential for subtype selectivity and combine with the well-characterized binding mode of fibrates to improve activity. These findings demonstrate the advantage of using 1H-pyrazolo-[3,4-b]pyridine as a skeleton of PPARα agonists and provide insight into the design of molecules for treating dyslipidemia.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyridines / PPAR alpha Type of study: Prognostic_studies Limits: Humans Language: En Journal: Sci Rep Year: 2020 Document type: Article Affiliation country: Japón

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyridines / PPAR alpha Type of study: Prognostic_studies Limits: Humans Language: En Journal: Sci Rep Year: 2020 Document type: Article Affiliation country: Japón